Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS

Regulatory approvals across the U.S., EU and China were the week's headline, accompanied by a number of acquisitions. Clinical readouts were mixed—several positive efficacy results in psoriasis, asthma and COPD were reported, but a few trials missed key goals—creating offsetting upside from approvals/acquisitions and downside from trial disappointments for biotech equities.

Analysis

Regulatory approvals across the U.S., EU and China were the week's headline, accompanied by a number of acquisitions. Clinical readouts were mixed—several positive efficacy results in psoriasis, asthma and COPD were reported, but a few trials missed key goals—creating offsetting upside from approvals/acquisitions and downside from trial disappointments for biotech equities.